Companies
Vaxcyte closes about $1.15 billion in equity and convertible offerings
Vaxcyte closed concurrent equity and 1.5% convertible notes for about $1.15B gross; underwriter options exercised; proceeds aim at VAX-31 adult and infant programs.
Desk byline
Claire Morgan
TickerGrove Healthcare Desk · Healthcare and biotech
Pharma, biotech, medtech, healthcare services, and material regulatory or clinical developments.
Claire Morgan is a TickerGrove AI-assisted newsroom contributor focused on healthcare and biotech. Reporting is built from source-backed research and passes TickerGrove verification, editorial and quality controls before publication.
Named bylines identify editorial desks, not independent human reporters.
This byline identifies TickerGrove Healthcare Desk reporting, checked against primary sources and dated evidence.
TickerGrove Healthcare Desk · How TickerGrove checks a claim · Corrections
Recent articles
Companies
Matchpoint closes $150 million Series B for oral autoimmune pipeline
Nextech and Norwest co-led; proceeds fund MPT-062 clinical proof of concept from 2027 and a continuing Novartis-funded program; Fierce Biotech also cites a $70 million Series A and $60 million Novartis upfront.
Companies
FDA clears Novartis Rhapsido as first treatment for symptomatic dermographism
RemIND showed a Week 12 complete Total Fric Score response of 29.3% with remibrutinib versus 14.0% with placebo; the label dose is 25 mg twice daily and carries a bleeding warning.
Companies
FDA clears Pfizer Tukysa with trastuzumab and pertuzumab for HER2 maintenance
HER2CLIMB-05 showed median progression-free survival of 24.9 months with tucatinib versus 16.3 months with placebo after induction, for a hazard ratio of 0.64; the label carries a boxed hepatotoxicity warning.
Companies
Asahi Kasei wins U.S. approval for oral Hovilpri in refractory herpes lesions
The Food and Drug Administration cleared the helicase-primase inhibitor for immunocompromised adults whose mucocutaneous sores did not respond to standard antivirals, with 63% healed by day 28 versus 34% on investigator's choice.
Companies
FDA clears Tecentriq with chemo after surgery for Stage III dMMR colon cancer
Atomic trial: disease-free survival hazard ratio 0.50; 36-month disease-free survival 86% with Tecentriq plus chemo versus 76% with chemo alone; twelfth U.S. Tecentriq indication.
Companies
Teva wins U.S. approval for monthly schizophrenia shot Weltruza
The once-monthly under-the-skin olanzapine shot is cleared for adults with schizophrenia; Teva says it needs no loading doses, oral top-up, or post-injection monitoring and will launch in coming weeks.
Companies
Humana beats its 2027 Medicare Star Ratings target and keeps its $9 profit guide
CMS final 2027 Stars (Bonus Year 2028) put Humana above its peer-median Stars revenue target; the insurer also affirmed at least $9.00 in 2026 adjusted earnings per share as open enrollment nears.